BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Glenmark Pharmaceuticals Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Glenmark Pharmaceuticals Ltd.'s d
 rugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06015048-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06015048)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2.\nStudy: A Trial of SHR-A1811
  Combined With Other Antitumor Therapies in Advanced Solid Tumors.\nEstima
 ted primary completion: November 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06015048
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024214-994@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 1/2 readout est. (NCT05024214)
DESCRIPTION:Envafolimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tu
 mors\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05024214
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or 
 SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05482568
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840002-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06840002)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Ovarian Cancer.\nStudy: A C
 linical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensiti
 ve Recurrent Ovarian Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 40002
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112991-994@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT05112991)
DESCRIPTION:Envafolimab\, phase 2\, Endometrial Cancer.\nStudy: Study of En
 vafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial C
 ancer\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05112991
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413745-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06413745)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Phase II Clinical Stud
 y of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally
  Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06413745
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05424835-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT05424835)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Tria
 l of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Po
 sitive\, Unresectable and/or Metastatic Breast Cancer Subjects Previously 
 Treated With Trastuzumab and Taxane\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05424835
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06828354-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06828354)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Ovarian Cancer.\nStudy: A Stu
 dy of SHR-A1811 in Subjects With Ovarian Cancer\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06828354
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123494-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06123494)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Gastric Cancer.\nStudy: SHR-A
 1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal J
 unction Adenocarcinoma After Progression on or After First-line Anti-HER2 
 Therapy-containing Regimen\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06123
 494
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04891198-994@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Envafolimab: Phase 2 readout est. (NCT04891198)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: ENVAFOLIMAB Single-agent Treatme
 nt in Patients With Advanced Solid Tumors\nEstimated primary completion: 3
 0 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/envafo
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04891198
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140393-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT07140393)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2.\nStudy: A Study of HRS-4508 
 in Combination With Other Anti-tumor Therapy for Solid Tumor\nEstimated pr
 imary completion: October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07140393
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Ph1b/
 2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced H
 ER2 Expression Gastric Cancer\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5671822
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07102901)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Safet
 y and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastr
 ic or Gastro-oesophageal Junction Adenocarcinoma\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07102901
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196774-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07196774)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoa
 djuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast
  Cancer\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196774
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123754-994@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Envafolimab: Phase 3 readout est. (NCT06123754)
DESCRIPTION:Envafolimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable
  Stage III NSCLC\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06123754
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111832-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07111832)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Clin
 ical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07111832
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796763-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07796763)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: A 
 Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chem
 otherapy and Bevacizumab as First-Line Treatment in Patients With Advanced
  Colorectal Cancer Expressing HER2\nEstimated primary completion: 1 May 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezet
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07796763
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06778031-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06778031)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: A Clinical Study of SH
 R-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic B
 iliary Tract Cancer\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06778031
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497386-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07497386)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Trial of Trastuzumab Rezetecan in Unresectable Locally Re
 current/Metastatic Breast Cancer\nEstimated primary completion: June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 497386
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910386-994@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Envafolimab: Phase 2 readout est. (NCT04910386)
DESCRIPTION:Envafolimab\, phase 2.\nStudy: Multicenter Phase 2 Study of Env
 afolimab in Biliary Tract Cancers\nEstimated primary completion: June 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04910386
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676162-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07676162)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Colorectal Cancer.\nStudy: A 
 Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizum
 ab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal
  Cancer\nEstimated primary completion: September 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07676162
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126640-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06126640)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Phas
 e III\, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine 
 (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual 
 Invasive Disease Following Neoadjuvant Therapy\nEstimated primary completi
 on: April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06126640
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07118527-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07118527)
DESCRIPTION:Trastuzumab rezetecan\, phase 3.\nStudy: A Phase III Study of S
 HR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Un
 treated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma\
 nEstimated primary completion: October 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07118527
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679360-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07679360)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Stud
 y of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investig
 ator's Choice of Therapy in Subjects With Residual Triple Negative Breast 
 Cancer\nEstimated primary completion: December 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07679360
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896005-9096@assetmemo.bio
DTSTAMP:20261121T004106Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07896005)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study of SHR-A1811 Combined With Adebrelimab for the First-line H
 ER2-overexpressing Non-squamous Non-small Cell Lung Cancer\nEstimated prim
 ary completion: February 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07896005
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
